Ahmed El Bastawisy
Overview
Explore the profile of Ahmed El Bastawisy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
57
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lu Y, Mahidin E, Azim H, Eralp Y, Yap Y, Im S, et al.
J Clin Oncol
. 2024 May;
42(23):2812-2821.
PMID: 38771995
Purpose: A head-to-head comparison of efficacy between a cyclin-dependent kinase 4/6 inhibitor plus endocrine therapy (ET) versus combination chemotherapy (CT) has never been reported in patients with clinically aggressive hormone...
2.
Schairer C, Hablas A, Eldein I, Gaafar R, Rais H, Mezlini A, et al.
Breast Cancer Res Treat
. 2020 Sep;
184(2):543-558.
PMID: 32876910
Purpose: Studies of the etiology of inflammatory breast cancer (IBC), a rare but aggressive breast cancer, have been hampered by limited risk factor information. We extend previous studies by evaluating...
3.
Mohamed O, El Bastawisy A, Allahlobi N, Abdellateif M, Zekri A, Shaarawy S, et al.
Diagn Pathol
. 2020 Feb;
15(1):10.
PMID: 32019558
Background: CD68+ tumor-associated macrophages (TAM) play an important role in the progression of classical Hodgkin lymphoma (cHL). We assessed the role of CD20 and CD68 + TAM in a cohort...
4.
Bahnasy A, El-Din R, Sabri N, Abdel-Rahman C, El Bastawisy A
Cancer Genet
. 2018 Dec;
228-229:83-92.
PMID: 30553477
Background: Malignant Pleural Mesothelioma (MPM) is a lethal cancer with few therapeutic options. Patients with MPM have a poor prognosis, with estimated 1 year median survival and currently no treatment...
5.
Ezzeldin N, El-Lebedy D, Darwish A, El Bastawisy A, Abd Elaziz S, Hassan M, et al.
BMC Cancer
. 2018 May;
18(1):525.
PMID: 29724170
Background: Several studies have reported the role of CYP2A6 genetic polymorphisms in smoking and lung cancer risk with some contradictory results in different populations. The purpose of the current study...
6.
Bogan D, Meile L, El Bastawisy A, Yousef H, Zekri A, Bahnassy A, et al.
BMC Cancer
. 2017 May;
17(1):329.
PMID: 28499366
Background: Breast cancer is the most globally diagnosed female cancer, with the triple negative breast cancer (TNBC) being the most aggressive subtype of the disease. In this study we aimed...
7.
Sinha A, Paul B, Sullivan L, Sims H, El Bastawisy A, Yousef H, et al.
Oncotarget
. 2017 Jan;
8(6):10114-10135.
PMID: 28052035
Tumor-initiating cells (TICs) are cancer cells endowed with self-renewal, multi-lineage differentiation, increased chemo-resistance, and in breast cancers the CD44+/CD24-/ALDH1+ phenotype. Triple negative breast cancers show lack of BRCA1 expression in...
8.
Abdallah A, Belal M, El Bastawisy A, Gaafar R
Oncol Lett
. 2014 Jun;
7(6):2121-2129.
PMID: 24932301
Currently, there is no serum marker that is routinely recommended for lung cancer. Therefore, the aim of the present study was to demonstrate that plasma vascular endothelial growth factor 165...
9.
Gaafar R, Abdel Rahman A, Aboulkasem F, El Bastawisy A
Ecancermedicalscience
. 2014 May;
8:424.
PMID: 24834119
Background: Malignant pleural effusion is a common problem in patients with solid tumours. It has a significant impact on quality of life, and, hence, there is a substantial need to...
10.
El Bastawisy A, El Azzouny M, Mohammed G, Allah A, Behiry E
Ecancermedicalscience
. 2014 Feb;
8:394.
PMID: 24567753
Introduction: Lung cancer is one of the most lethal malignancies; however, no serum marker has been routinely recommended until now. Methods: THIS IS A PROSPECTIVE CASE CONTROL STUDY INCLUDING TWO...